Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- Ege University
- Target Recruit Count
- 30
- Registration Number
- NCT00873496
- Locations
- 🇹🇷
Ege University School of Dentistry, Izmir, Bornova, Turkey
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00813423
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 11
- Registration Number
- NCT00786682
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
🇺🇸Overlook Hospital, Summit, New Jersey, United States
Hydroxychloroquine in Untreated B-CLL Patients
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 23
- Registration Number
- NCT00771056
- Locations
- 🇺🇸
Long Island Jewish Medical Center CLL Research and Treatment Center, New Hyde Park, New York, United States
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2008-10-03
- Last Posted Date
- 2023-08-09
- Target Recruit Count
- 6
- Registration Number
- NCT00765765
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2017-05-23
- Target Recruit Count
- 8
- Registration Number
- NCT00728845
- Locations
- 🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
🇺🇸Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 64
- Registration Number
- NCT00726596
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, New Jersey, United States
🇺🇸Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2016-02-18
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 38
- Registration Number
- NCT00714181
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 120
- Registration Number
- NCT00632866
- Locations
- 🇫🇷
Hopital Bicëtre, Le Kremlin Bicetre, France
Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT00568880
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.